All news - 2 October, 2024
Real Estate Mogul Jonathan Holtzman Faces $69M Foreclosure: Chicago's Market on Edge Amid Rising Financial Pressures
Amazon Faces NLRB Charges: Shifting Operations Amid Union Battles and Boosting PR Efforts
General Dynamics Reports Strong Q2 Growth Amid Rising Global Defense Demand, Stock Positioned for Further Gains
Tesla's Q3 2024: Missed Delivery Targets, Rising Competition, and Future Hinges on Cybertruck and Robotaxi
Dream Machine 1.6 by Luma AI Revolutionizes Video Creation with 10x Faster Speed and Cinematic Control
Stellantis Faces Sharp Q3 2024 Sales Decline: Restructuring and New CEO likely on the Horizon
Synchron’s Groundbreaking Stentrode BCI Shows Promising Results in 12-Month Paralysis Trial, Paving the Way for Thought-Controlled Devices
OpenAI Secures $6.6 Billion in Funding, Reaches $157 Billion Valuation: Dominating the AI Revolution
Pika Labs Unveils Pika 1.5 with Groundbreaking 'Pikaffects' and Cinematic Enhancements
Formality Secures €8 Million to Transform Contract Management with AI-Driven Innovation
Russia Seizes Key Ukrainian Town of Vuhledar, Shifting War Momentum Ahead of Winter
Starling Bank Hit with £29 Million Fine by FCA: A Wake-Up Call for Fintech Compliance and Growth
Humana Stock Plunges 20% After Major Medicare Ratings Downgrade, Raising Concerns for 2026 Profits
OpenAI Reinforces Generative AI Leadership with Game-Changing Realtime API and Multimodal Innovations
Bitwise Files for XRP ETF Amid Investor Skepticism as XRP Drops 4%
Snap Employees Sounded the Alarm on Sextortion, but CEO Spiegel’s Aggressive Leadership and Toxic Culture Stifled Action
Crypto Could Tip the Scales: How Digital Currency is Shaping the 2024 Presidential Election
Israel Unfazed by Iran’s Missile Strike: Escalating Tensions, Nuclear Threats, and Rising Fears of World War 3
JD Vance Shines in 2024 VP Debate, Sparking Buzz for Future Presidential Run
LabElite Co-Owner Pleads Guilty in $14 Million COVID-19 Testing Fraud Scandal: Luxury Cars, Millions Seized
NYC Hotel Licensing Bill Sparks Controversy: Threatens Small Businesses, Gig Economy, and Consumer Costs
Genentech Acquires Regor’s CDK Inhibitors in $850M Deal to Revolutionize Breast Cancer Treatment
